FDA grants full approval for Gilead's long-acting injectable lenacapavir for HIV prevention

The FDA granted approval for a long-acting injectable version of Gilead Sciences' lenacapavir for HIV prevention, administered twice yearly as an alternative to daily PrEP pills. The approval aims to improve medication adherence and reduce stigma associated with daily treatment.

Detected & updated continuously · Source: Nebula